Author:
Huang Rukun,Lin Tingsheng,Chen Mengxia,Li Xiaogong,Guo Hongqian
Abstract
Abstract
Background
It is extremely essential to accurately differentiate pheochromocytoma from Adrenal incidentalomas (AIs) before operation, especially biochemical tests were inconclusive. We aimed to evaluate the value of magnetic resonance imaging (MRI) features to differentiate pheochromocytomas among adrenal tumors, among which the consequences of biochemical screening tests of catecholamines and/or catecholamine metabolites are positive.
Methods
With institutional review board approval, this study retrospectively compared 35 pheochromocytoma (PHEO) patients with 27 non-pheochromocytoma(non-PHEO) patients between January 2022 to September 2023, among which the consequences of biochemical screening tests of catecholamines and/or catecholamine metabolites are positive. T test was used for the independent continuous data and the chi-square test was used for categorical variables. Univariate and multivariate logistic regression were applied to find the independent variate of the features to differentiate PHEO from non-PHEO and ROC analysis was applied to evaluate the diagnostic value of the independent variate.
Results
We found that the T2-weighted (T2W) signal intensity in patients with pheochromocytoma was higher than other adrenal tumors, with greatly significant (p < 0.001). T2W signal intensity ratio (T2W nodule-to-muscle SI ratio) was an independent risk factor for the differential diagnosis of adrenal PHEOs from non-PHEOs. This feature alone had 91.4% sensitivity and 81.5% specificity to rule out pheochromocytoma based on optimal threshold, with an area under the receiver operating characteristics curve (AUC‑ROC) of 0.910(95% C I: 0.833–0.987).
Conclusion
Our study confirms that T2W signal intensity ratio can differentiate PHEO from non-PHEO, among which the consequences of biochemical screening tests of catecholamines and/or catecholamine metabolites are positive.
Funder
National Natural Science Foundation of China
Jiangsu Province Science and Technology Project Social Development General Program
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Young WFJ. Clinical practice.The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601–10.
2. Glazer DI, Mayo-Smith WW. Management of incidental adrenal masses: an update. Abdom Radiol. 2020;45(4):892–900.
3. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1–34.
4. Araujo-Castro M, Iturregui Guevara M, Calatayud Gutierrez M, Parra Ramirez P, Gracia Gimeno P, Hanzu FA, Lamas Oliveira C. Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas adrenal diseases Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol Diabetes Nutr (Engl Ed). 2020;67(6):408–19.
5. Young WF. Management approaches to adrenal incidentalomas - a view from Rochester, Minnesota. Endocrin Metab Clin. 2000;29(1):159–.